Wu Haidong, deputy director of the Ministry of industry and information technology: good innovation at the beginning of the 13th five year plan of the pharmaceutical industry is the key to development

Source: Sina Pharmaceutical News 2016-12-01 on November 7, six ministries and commissions including the Ministry of industry and information technology jointly issued the guidelines for the development of pharmaceutical industry, which will receive key support from the state in many fields; in October, the State Council issued the healthy China 2030 The outline of the plan promotes the health China strategy to an unprecedented level, and the pharmaceutical and health industry will usher in a feast of over 8 trillion capital The structural opportunities of the pharmaceutical industry emerge, and the golden development period will come again How can pharmaceutical enterprises grasp the strategic opportunities? Wu Haidong, deputy director of the consumer goods department of the Ministry of industry and information technology of the people's Republic of China, made an in-depth interpretation of this year's development of the pharmaceutical industry and its future development plan at the 6th president (expansion) meeting of the 7th session of China Pharmaceutical Enterprise Management Association and the 30th China Pharmaceutical Industry Development Summit Forum held in Kunming, Yunnan Province on November 30 Although many reports describe the cold winter of capital in the pharmaceutical industry this year, the data shows that the pharmaceutical industry still maintains a good growth rate In the first three quarters, GDP grew by 6.7% year-on-year, and the pharmaceutical industry grew by 10.4% year-on-year It is the only industry with a growth rate of more than two digits, which can be said to have contributed to the stable growth of the national economy At the same time, the proportion of the pharmaceutical industry in the total industry has gradually increased, from 3% at the end of last year to 3.3% in January September The overall growth of the pharmaceutical industry is good What about the efficiency indicators? From January to September, the main revenue of the pharmaceutical industry was 2.1 trillion, up 10.1% year on year, higher than 6.4% of the total industry The total profit of the pharmaceutical industry is 220 billion yuan, up 15.6% year on year, higher than 7.2% of the total industry Compared with the profit realized, the growth rate of the main business income is 5.5% higher than that of the main business income, and the sales profit rate reaches 10.4%, which shows that the operation quality of the pharmaceutical industry from January to September is also relatively high From the above data, it can be proved that the 13th five year plan of the pharmaceutical industry started well, contributed to the stable growth of the national economy, and the pharmaceutical industry has a good operation stability However, many changes in the market environment and policy environment have brought unprecedented challenges to the production and operation of enterprises, which cannot be ignored The operation of the pharmaceutical industry is generally in the period of bottom adjustment, with both upward power and downward pressure On November 7, the Ministry of industry and information technology, the national development and Reform Commission, the Ministry of science and technology, the Ministry of Commerce, the state health and Family Planning Commission and the State Food and Drug Administration jointly issued the guideline for the development planning of the pharmaceutical industry The guideline, as a special planning guideline for the development of the pharmaceutical industry during the 13th Five Year Plan period, has four characteristics: First, the plan emphasizes the function of medicine to serve the people's livelihood, so that people have more sense of access "13th five year plan" will build a well-off society in an all-round way, and people's health is an important foundation for a well-off society in an all-round way The pharmaceutical industry must make new contributions to meet the medical and health care needs of the people and promote the construction of a healthy China Second, the five concepts of innovation, coordination, green, openness and sharing run through the whole planning Innovation is the first driving force to lead the development of medicine Continuous upgrading of existing products is the basis for the transformation and upgrading of medicine from big to strong The pharmaceutical industry adheres to innovation driven, providing high-quality drugs is to protect people's health, at the same time, the pharmaceutical industry to achieve green development, building a beautiful China is also to protect people's health, the production of drugs, especially raw materials must be energy-saving and emission reduction, towards green development! The third is to promote supply side structural reform as the main line The plan will focus on solving the problems of insufficient high-end innovative products, shortage of clinically necessary products, uneven product quality and insufficient brand influence We should strive to improve the quality and efficiency of supply, promote the coordination and progress of supply upgrading and demand upgrading, and promote the pharmaceutical industry to a high level of supply-demand balance Fourth, we should strive to cultivate large enterprises with international competitiveness The characteristics of pharmaceutical enterprises are how small and scattered, how to cultivate large enterprises with international competitiveness, and how to steadily improve the level of scale economy and industrial concentration of pharmaceutical industry, which has become a pressing issue During the 13th Five Year Plan period, the government departments should form a joint force, improve the mechanism of survival of the fittest, force backward production capacity, backward enterprises and backward technology to withdraw, encourage the strong and strong combination of advantageous enterprises, and carry out large-scale merger and reorganization Wu Haidong also said at the meeting: "at present, the major problem that the pharmaceutical industry should strive to solve is to rely on innovation closely, realize the digitalization and even intelligence of production process control, so as to ensure the safety and effectiveness of drugs The safety and effectiveness of drugs is the first intention of Chinese pharmaceutical people, and we should never forget the first intention."